RenovoRx (RNXT) announced that the Japan Patent Office has issued a Notice of Allowance for the company’s first Japanese patent application titled “Method and Apparatus for Delivering an Agent Through the Vasa Vasorum.” “This Japanese patent allowance represents an important milestone in expanding RenovoRx’s global intellectual property footprint and underscores a significant advancement in targeted drug-delivery utilizing these micro vessels as a pathway to reach difficult-to-treat tumors,” said Shaun Bagai, CEO of RenovoRx.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT: